LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced the ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

A “Validated” column in the DDI perpetrator table to clearly identify the values that have been validated by our DDI experts for use in simulations Dr. Michael Bolger, Founding Scientist of Simulation ...

Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O ...

Image source: The Motley Fool. Need a quote from one of our analysts? Email [email protected] Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

Simulations Plus faces soft revenue growth in the short term, due largely to macro conditions. The negatives appear to have been priced in, though, after a period of significant share price declines.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced the ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods ...